Requires Adobe Acrobat ReaderRequires Adobe Acrobat Reader| Organ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Heart-Lung | Heart | Intestine | Kidney | KP | Liver | Lung | PAK | PTA | |||
| Transplants (2008) | 27 | 2,163 | 185 | 16,517 | 836 | 6,318 | 1,478 | 214 | 223 | ||
| Tx With Immunosuppression Info at Discharge | 22 | 2,110 | 182 | 16,250 | 823 | 6,125 | 1,436 | 206 | 219 | ||
| Induction Drug Reported | 72.7% | 52.3% | 59.9% | 81.5% | 83.4% | 26.6% | 62.7% | 79.6% | 73.1% | ||
| Induction Drugs | Atgam/NRATG/NRATS | 13.6% | 6.5% | 0.0% | 1.5% | 1.5% | 1.1% | 7.1% | 1.0% | 1.4% | |
| OKT3 | 0.0% | 1.4% | 15.4% | 1.0% | 1.0% | 2.5% | 0.7% | 1.0% | 6.4% | ||
| Thymoglobulin | 0.0% | 18.1% | 33.5% | 44.8% | 59.8% | 10.3% | 4.5% | 51.9% | 49.8% | ||
| Zenapax | 40.9% | 11.1% | 8.2% | 10.9% | 6.1% | 7.9% | 14.0% | 4.4% | 6.8% | ||
| Simulect | 4.5% | 14.0% | 0.5% | 17.8% | 8.4% | 6.7% | 28.8% | 8.3% | 4.6% | ||
| Campath | 13.6% | 3.4% | 18.1% | 10.7% | 9.8% | 1.0% | 9.2% | 15.0% | 11.4% | ||
| Tx With Immunosuppression Info and Functioning Graft at Discharge | 20 | 2,026 | 167 | 16,000 | 815 | 5,826 | 1,358 | 192 | 201 | ||
| Maintenance at Discharge | Corticosteroids Use | 100.0% | 87.4% | 78.4% | 66.2% | 70.1% | 80.0% | 98.2% | 59.9% | 56.7% | |
| Steroids | 100.0% | 87.4% | 78.4% | 66.2% | 70.1% | 80.0% | 98.2% | 59.9% | 56.7% | ||
| Calcineurin Inhibitor Use | 100.0% | 98.7% | 100.0% | 95.9% | 98.4% | 98.0% | 98.9% | 96.9% | 99.0% | ||
| Cyclosporine | 10.0% | 25.6% | 0.6% | 7.6% | 4.4% | 7.0% | 8.4% | 3.6% | 1.5% | ||
| Tacrolimus | 90.0% | 72.5% | 98.8% | 87.8% | 93.3% | 90.4% | 89.3% | 92.7% | 97.5% | ||
| Everolimus | 0.0% | 0.6% | 0.6% | 0.5% | 0.7% | 0.6% | 1.2% | 0.5% | 0.0% | ||
| Antimetabolite Use | 95.0% | 92.5% | 24.6% | 93.4% | 91.2% | 77.0% | 91.4% | 93.8% | 62.2% | ||
| Mycophenolate Mofetil | 85.0% | 87.1% | 24.0% | 74.1% | 72.5% | 71.3% | 54.3% | 79.2% | 55.7% | ||
| Mycophenolate Sodium | 5.0% | 2.7% | 0.0% | 18.5% | 18.5% | 5.3% | 8.7% | 13.0% | 6.0% | ||
| Azathioprine | 5.0% | 2.8% | 0.6% | 0.8% | 0.1% | 0.4% | 28.4% | 1.0% | 0.5% | ||
| Leflunomide | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.5% | 0.0% | ||
| mTOR Inhibitor Use | 0.0% | 3.4% | 9.6% | 4.1% | 8.0% | 2.2% | 0.4% | 7.8% | 10.9% | ||
| Sirolimus | 0.0% | 1.0% | 9.6% | 4.1% | 8.0% | 2.1% | 0.4% | 7.8% | 10.9% | ||
| Everolimus | 0.0% | 2.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||
| Transplants (2007) | 31 | 2,209 | 198 | 16,630 | 862 | 6,494 | 1,471 | 261 | 208 | ||
| Tx With Maintenance Use at 1yr PostTx | 26 | 1,896 | 139 | 14,693 | 755 | 5,131 | 1,150 | 206 | 150 | ||
| Maintenance at 1yr PostTx | Corticosteroids Use | 100.0% | 66.0% | 68.3% | 64.1% | 67.5% | 35.1% | 98.6% | 55.3% | 53.3% | |
| Steroids | 100.0% | 66.0% | 68.3% | 64.1% | 67.5% | 35.1% | 98.6% | 55.3% | 53.3% | ||
| Calcineurin Inhibitor Use | 100.0% | 97.1% | 98.6% | 94.1% | 97.9% | 92.7% | 98.2% | 97.1% | 96.7% | ||
| Cyclosporine | 7.7% | 27.8% | 1.4% | 9.7% | 6.9% | 8.2% | 9.8% | 5.3% | 2.7% | ||
| Tacrolimus | 92.3% | 68.9% | 96.4% | 84.0% | 90.6% | 84.2% | 87.8% | 90.8% | 94.0% | ||
| Everolimus | 0.0% | 0.4% | 0.7% | 0.5% | 0.4% | 0.4% | 0.5% | 1.0% | 0.0% | ||
| Antimetabolite Use | 57.7% | 88.1% | 10.1% | 88.4% | 84.8% | 49.6% | 80.2% | 87.9% | 56.7% | ||
| Mycophenolate Mofetil | 46.2% | 75.7% | 8.6% | 65.6% | 62.1% | 43.0% | 48.8% | 70.4% | 46.7% | ||
| Mycophenolate Sodium | 3.8% | 6.9% | 0.0% | 20.7% | 21.2% | 5.8% | 8.8% | 15.0% | 8.0% | ||
| Azathioprine | 7.7% | 5.4% | 1.4% | 1.4% | 1.1% | 0.8% | 22.5% | 1.0% | 2.0% | ||
| Leflunomide | 0.0% | 0.1% | 0.0% | 0.7% | 0.4% | 0.0% | 0.1% | 1.5% | 0.0% | ||
| mTOR Inhibitor Use | 3.8% | 9.3% | 6.5% | 8.3% | 13.9% | 8.3% | 6.6% | 18.0% | 20.0% | ||
| Sirolimus | 3.8% | 6.9% | 6.5% | 8.0% | 13.9% | 8.3% | 6.6% | 18.0% | 20.0% | ||
| Everolimus | 0.0% | 2.5% | 0.0% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | ||
Requires Adobe Acrobat Reader